Market Access Capping the cost of insulin: altruistic or strategic? The price of insulin has become one of the most talked about issues across the pharma industry.
News Twitter trolls, Musk's changes tank stocks for Lilly, other ... Elon Musk's Twitter takeover has been nothing if not tumultuous, and that tumult hit home for pharma Thursday, when an account impersonating Eli Lilly and Company - taking advantage of lax
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
